Citigroup
ABOS icon

Citigroup’s Acumen Pharmaceuticals ABOS Stock Holding History

Citigroup’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.4K Buy
21,889
+17,403
+388% +$43K ﹤0.01% 4921
2026
Q1 		$10.6K Buy
+4,486
New +$11.4K ﹤0.01% 5015
2025
Q4 		– Sell
-151
Closed -$258 – 6011
2025
Q3 		$258 Sell
151
-2,964
-95% -$4.1K ﹤0.01% 5748
2025
Q2 		$3.61K Sell
3,115
-26,721
-90% -$28.7K ﹤0.01% 5317
2025
Q1 		$32.8K Sell
29,836
-50,509
-63% -$72.1K ﹤0.01% 4989
2024
Q4 		$138K Buy
80,345
+49,753
+163% +$120K ﹤0.01% 4658
2024
Q3 		$75.9K Buy
30,592
+21,177
+225% +$57.4K ﹤0.01% 4885
2024
Q2 		$22.8K Sell
9,415
-125,979
-93% -$401K ﹤0.01% 4967
2024
Q1 		$548K Sell
135,394
-12,417
-8% -$46.8K ﹤0.01% 3503
2023
Q4 		$568K Buy
147,811
+109,313
+284% +$324K ﹤0.01% 3309
2023
Q3 		$160K Buy
38,498
+37,801
+5,423% +$234K ﹤0.01% 3764
2023
Q2 		$3.35K Sell
697
-40,680
-98% -$195K ﹤0.01% 5229
2023
Q1 		$168K Sell
41,377
-4,197
-9% -$21.9K ﹤0.01% 3821
2022
Q4 		$246K Buy
45,574
+37,258
+448% +$250K ﹤0.01% 3617
2022
Q3 		$83K Buy
8,316
+7,385
+793% +$42.4K ﹤0.01% 4174
2022
Q2 		$4K Sell
931
-2,762
-75% -$10.4K ﹤0.01% 5655
2022
Q1 		$14K Sell
3,693
-198
-5% -$1.08K ﹤0.01% 5349
2021
Q4 		$26K Buy
3,891
+2,797
+256% +$30.7K ﹤0.01% 5313
2021
Q3 		$16K Buy
+1,094
New +$18.2K ﹤0.01% 5316

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citigroup's ABOS Position: Q2 2026 in Review

Citigroup increased its Acumen Pharmaceuticals (ABOS) stake by 388% in Q2 2026, buying an estimated $43K and bringing the position to 21,889 shares worth $58.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4921.

Citigroup first reported a position in ABOS in Q3 2021 and has held it in 19 quarters since. The position peaked at $568K in Q4 2023. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Citigroup held 21,889 shares of Acumen Pharmaceuticals worth $58.4K as of Q2 2026.
  • Citigroup bought 17,403 Acumen Pharmaceuticals shares in Q2 2026, an estimated $43K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4921 holding.
  • Citigroup first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Citigroup's Acumen Pharmaceuticals position peaked at $568K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.